Managing ADHD Medication Crash with Dose Optimization

Introduction to Dose Optimization

The American Academy of Child and Adolescent Psychiatry recommends adding a short-acting stimulant booster dose in the afternoon when long-acting stimulants like Vyvanse wear off, to manage breakthrough ADHD symptoms in patients with individual pharmacokinetic variability 1

Adding a low-dose immediate-release stimulant booster (5-10mg methylphenidate or 2.5-5mg mixed amphetamine salts) in the early afternoon can help manage the crash, rather than taking Vyvanse earlier or increasing the dose 1
The booster dose should be administered around 2-3 PM, when Vyvanse effects begin to wane, and takes effect within 30 minutes, providing 4-6 hours of additional coverage 1, 2
Critical timing consideration: Do NOT administer the booster after 3-4 PM to prevent insomnia 1, 2

Check blood pressure and pulse with the addition of the booster dose 2
Monitor for cumulative side effects: appetite suppression, insomnia, and rebound irritability may worsen with combination therapy 3
Weigh the patient at follow-up visits to detect potential weight loss from appetite suppression 2
Document that the current dose controls symptoms adequately during its active period but fails to provide sufficient duration, and that the combined regimen does not produce prohibitive side effects 1

Before adding a booster, trialing increasing Vyvanse to 30mg to see if this extends duration of coverage may be considered, as adults may require higher total daily doses than children 4
However, if 30mg still doesn't provide evening coverage, the booster strategy becomes the appropriate next step 1

Untreated ADHD symptoms during evening hours can lead to substantial functional impairment and reduced quality of life 3
Effective management of the crash is crucial to prevent significant impairment in evening activities, homework, social functioning, or work completion 3

Don't dose the afternoon booster too late: Administration after 4-5 PM significantly increases insomnia risk 1, 3
Don't assume the patient needs to "push through" the crash: This represents true symptom breakthrough requiring pharmacological management 1
Don't switch medications entirely without trying dose optimization first: The patient has good response to Vyvanse during its active period 1
Don't confuse behavioral rebound with true symptom breakthrough: True breakthrough requires additional medication coverage 3

In patients receiving immediate‑release mixed amphetamine salts, the expected therapeutic window is 4–6 hours; however, a 5 mg afternoon dose provided only about 2 hours of symptom control, indicating sub‑therapeutic coverage for afternoon breakthrough symptoms. This observation is supported by evidence from the American Academy of Child and Adolescent Psychiatry. 5